Biosimilar Monoclonal Antibody Market 2025 to 2034
Biosimilar Monoclonal Antibody Market 2025 to 2034
Biosimilar Monoclonal Antibody Market (By Type: Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others; By Indication: Oncology, Autoimmune diseases, Others; By End User: Hospitals, Cancer treatment centers, Others; By Region: North America, LAMEA, Europe, Asia-Pacific) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034
Customisation Request
Revenue, 2025
USD 16.01 Bn
Forecast Year, 2034
USD 104.71 Bn
CAGR, 2025 - 2034
23.20
Report Coverage
Worldwide
Published By
Saurabh Bidwai
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
The global biosimilar monoclonal antibody market, valued at USD 16.01 billion in 2025, is projected to surge to USD 104.71 billion by 2034, expanding at a robust CAGR of 23.2%, driven by rising biologics adoption, patent expirations, and growing healthcare demand.
Biosimilar Monoclonal Antibody Market Size Analysis
Biosimilar Monoclonal Antibody Market Size By Type 2025 to 2034 (USD Billion)
| Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | 0.77 | 0.94 | 1.17 | 1.45 | 1.78 | 2.16 | 2.67 | 3.33 | 4.06 | 5.06 |
| Bevacizumab | 1.53 | 1.89 | 2.32 | 2.85 | 3.53 | 4.33 | 5.33 | 6.60 | 8.08 | 10.04 |
| Infliximab | 2.29 | 2.82 | 3.47 | 4.27 | 5.26 | 6.51 | 8.00 | 9.83 | 12.15 | 15.00 |
| Rituximab | 3.04 | 3.75 | 4.62 | 5.70 | 7.02 | 8.64 | 10.67 | 13.15 | 16.22 | 19.89 |
| Trastuzumab | 3.80 | 4.69 | 5.78 | 7.12 | 8.76 | 10.81 | 13.34 | 16.39 | 20.20 | 24.88 |
| Others | 4.57 | 5.64 | 6.94 | 8.55 | 10.53 | 12.98 | 15.97 | 19.67 | 24.25 | 29.83 |
Biosimilar Monoclonal Antibody Market Size By Indication 2025 to 2034 (USD Billion)
| Indication | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | 2.69 | 3.33 | 4.08 | 4.99 | 6.22 | 7.57 | 9.43 | 11.50 | 14.23 | 17.57 |
| Autoimmune diseases | 5.35 | 6.56 | 8.12 | 9.96 | 12.25 | 15.17 | 18.62 | 23.03 | 28.21 | 34.88 |
| Others | 7.97 | 9.83 | 12.10 | 14.99 | 18.41 | 22.69 | 27.94 | 34.43 | 42.53 | 52.24 |
Biosimilar Monoclonal Antibody Market Size By End User 2025 to 2034 (USD Billion)
| End User | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | 2.69 | 3.28 | 4.10 | 4.99 | 6.18 | 7.67 | 9.41 | 11.57 | 14.12 | 17.49 |
| Cancer treatment centers | 5.32 | 6.56 | 8.10 | 9.97 | 12.30 | 15.14 | 18.67 | 22.88 | 28.46 | 34.90 |
| Others | 8.00 | 9.88 | 12.09 | 14.98 | 18.40 | 22.63 | 27.90 | 34.52 | 42.39 | 52.29 |
Biosimilar Monoclonal Antibody Market Size By Region 2025 to 2034 (USD Billion)
| Region | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | 1.62 | 1.97 | 2.45 | 3.01 | 3.69 | 4.58 | 5.62 | 6.90 | 8.60 | 10.53 |
| LAMEA | 3.21 | 3.95 | 4.85 | 6.01 | 7.36 | 9.12 | 11.18 | 13.83 | 16.94 | 21.01 |
| Europe | 4.81 | 5.91 | 7.28 | 8.97 | 11.08 | 13.61 | 16.80 | 20.66 | 25.55 | 31.40 |
| Asia-Pacific | 6.38 | 7.89 | 9.72 | 11.95 | 14.76 | 18.13 | 22.38 | 27.57 | 33.88 | 41.74 |
Biosimilar Monoclonal Antibody Market Size to Hit USD 104.71 Billion by 2034
The global biosimilar monoclonal antibody market size is calculated at USD 16.01 billion in 2025 and is predicted to attain around USD 104.71 billion by 2034 with a expanding at a CAGR of 23.20%.
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
